• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黑热病后皮肤利什曼病(PKDL)的免疫病理学:T细胞表型和细胞因子谱

Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.

作者信息

Ismail A, El Hassan A M, Kemp K, Gasim S, Kadaru A E, Moller T, Kharazmi A, Theander T G

机构信息

Centre for Medical Parasitology, Institute of Medical Microbiology and Immunology, University of Copenhagen, Denmark.

出版信息

J Pathol. 1999 Dec;189(4):615-22. doi: 10.1002/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z.

DOI:10.1002/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z
PMID:10629566
Abstract

In Sudan, post kala-azar dermal leishmaniasis (PKDL) caused by Leishmania donovani develops in half of the patients treated for visceral leishmaniasis (kala-azar). In most patients lesions heal spontaneously, but in others symptoms are severe and persist for years. This study examined the immunological response in lesions of PKDL patients by immunohistochemistry and compared the findings with results obtained using peripheral blood mononuclear cells (PBMCs). In all lesions, parasites or parasite antigen were present and provoked the formation of an inflammatory infiltrate consisting of a mixture of macrophages, lymphocytes, and plasma cells. In patients who had high interferon-gamma (IFNgamma) responses to Leishmania antigen in vitro, compact epithelioid granulomas were formed. The inflammatory cells were mainly CD3(+) and interleukin-10 (IL10) was the most prominent cytokine in the lesions. However, IFNgamma was found in all and IL4 in most lesions, in varying amounts. PBMCs from all patients responded to Leishmania antigen by IFNgamma production or proliferation. The results indicate that PKDL develops as a result of an influx of immunocompetent cells into skin, which harbours parasites. The inflammatory response to the parasites is complex. It involves several cell types and cytokines, of which some are antagonistic. It is conceivable that the balance between these cytokines determines the outcome of the disease.

摘要

在苏丹,由杜氏利什曼原虫引起的黑热病后皮肤利什曼病(PKDL)发生在一半接受内脏利什曼病(黑热病)治疗的患者中。大多数患者的皮损会自发愈合,但其他患者的症状严重且会持续数年。本研究通过免疫组织化学检查了PKDL患者皮损中的免疫反应,并将结果与使用外周血单个核细胞(PBMC)获得的结果进行比较。在所有皮损中,均存在寄生虫或寄生虫抗原,并引发了由巨噬细胞、淋巴细胞和浆细胞混合组成的炎性浸润。在体外对利什曼原虫抗原有高干扰素-γ(IFNγ)反应的患者中,形成了致密的上皮样肉芽肿。炎性细胞主要为CD3(+),白细胞介素-10(IL10)是皮损中最突出的细胞因子。然而,在所有皮损中均发现了IFNγ,大多数皮损中也发现了IL4,含量各不相同。所有患者的PBMC通过产生IFNγ或增殖对利什曼原虫抗原作出反应。结果表明,PKDL是由于免疫活性细胞流入寄生有寄生虫的皮肤而发生的。对寄生虫的炎症反应很复杂。它涉及多种细胞类型和细胞因子,其中一些具有拮抗作用。可以想象,这些细胞因子之间的平衡决定了疾病的转归。

相似文献

1
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.黑热病后皮肤利什曼病(PKDL)的免疫病理学:T细胞表型和细胞因子谱
J Pathol. 1999 Dec;189(4):615-22. doi: 10.1002/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z.
2
Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.白细胞介素-10和IgG3水平升高是印度黑热病后皮肤利什曼病的特征。
J Infect Dis. 2008 Jun 15;197(12):1762-71. doi: 10.1086/588387.
3
Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.γ干扰素、肿瘤坏死因子-α、白细胞介素-6和γ干扰素受体1是与黑热病后皮肤利什曼病相关的主要免疫决定因素。
J Infect Dis. 2006 Oct 1;194(7):958-65. doi: 10.1086/506624. Epub 2006 Aug 23.
4
The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?从现场到分子水平:黑热病后皮肤利什曼病的发病机制——紫外线(UVB)辐射是否起作用?
Med Hypotheses. 2006;66(5):993-9. doi: 10.1016/j.mehy.2005.03.035. Epub 2006 Jan 4.
5
Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.印度黑热病后皮肤利什曼病单形和多形临床形式的细胞免疫反应评估。
Clin Exp Immunol. 2016 Jul;185(1):50-60. doi: 10.1111/cei.12787. Epub 2016 May 4.
6
Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.增强的病灶 Foxp3 表达和外周无反应性淋巴细胞表明调节性 T 细胞在印度晚发性皮肤利什曼病中起作用。
J Invest Dermatol. 2010 Apr;130(4):1013-22. doi: 10.1038/jid.2009.393. Epub 2009 Dec 24.
7
Post-kala-azar dermal leishmaniasis--an overview.Post-kala-azar dermal leishmaniasis--an overview.
Int J Dermatol. 2010 Aug;49(8):921-31. doi: 10.1111/j.1365-4632.2010.04558.x.
8
Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.评估血清学标志物以监测印度内脏利什曼病皮肤后时期的疾病状态。
Trans R Soc Trop Med Hyg. 2012 Nov;106(11):668-76. doi: 10.1016/j.trstmh.2012.07.005. Epub 2012 Aug 21.
9
Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.利用重组蛋白 K39 诊断尼泊尔黑热病后皮肤利什曼病
Southeast Asian J Trop Med Public Health. 2007 Jul;38(4):619-25.
10
Lesional T-cell subset in post-kala-azar dermal leishmaniasis.黑热病后皮肤利什曼病的皮损T细胞亚群
Int J Dermatol. 2005 Jan;44(1):12-3. doi: 10.1111/j.1365-4632.2004.01579.x.

引用本文的文献

1
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.免疫治疗策略作为皮肤利什曼病的潜在治疗选择
Vaccines (Basel). 2024 Oct 17;12(10):1179. doi: 10.3390/vaccines12101179.
2
Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome.苏丹内脏利什曼病治愈后患者的细胞免疫反应差异及其对结局的可能影响。
J Epidemiol Glob Health. 2024 Sep;14(3):1167-1179. doi: 10.1007/s44197-024-00270-0. Epub 2024 Jul 15.
3
Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
无鞭毛体利什曼病(PKDL)药物疗效研究现状:一项系统评价临床试验和观察性研究的范围界定,以评估建立个体参与者水平数据(IPD)平台的可行性。
PLoS Negl Trop Dis. 2024 Apr 16;18(4):e0011635. doi: 10.1371/journal.pntd.0011635. eCollection 2024 Apr.
4
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.印度次大陆的无黑热病皮肤利什曼病:消除的挑战与策略。
Front Immunol. 2023 Aug 11;14:1236952. doi: 10.3389/fimmu.2023.1236952. eCollection 2023.
5
Major Molecular Factors Related to Pathogenicity.主要与致病性相关的分子因素。
Front Immunol. 2022 Jun 13;13:847797. doi: 10.3389/fimmu.2022.847797. eCollection 2022.
6
Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL).皮肤利什曼病和内脏利什曼病后皮肤利什曼病(PKDL)的免疫发病机制。
Front Cell Infect Microbiol. 2021 Jun 8;11:685296. doi: 10.3389/fcimb.2021.685296. eCollection 2021.
7
Immune Responses in Post Kala-azar Dermal Leishmaniasis.黑热病后皮肤利什曼病中的免疫反应
Indian J Dermatol. 2020 Nov-Dec;65(6):452-460. doi: 10.4103/ijd.IJD_258_20.
8
Differential Regulation of miRNA Profiles of Human Cells Experimentally Infected by Isolated From Indian Visceral Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis.从印度内脏利什曼病和黑热病后皮肤利什曼病中分离出的[病原体名称未给出]实验感染的人类细胞miRNA谱的差异调控 。 (注:原文中“Isolated From Indian Visceral Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis.”前缺少具体的病原体等关键信息,导致译文不太完整准确)
Front Microbiol. 2020 Jul 31;11:1716. doi: 10.3389/fmicb.2020.01716. eCollection 2020.
9
Post kala-azar dermal leishmaniasis: A threat to elimination program.无鞭毛体利什曼原虫病皮肤后:消除规划的威胁。
PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008221. doi: 10.1371/journal.pntd.0008221. eCollection 2020 Jul.
10
Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.用于宿主导向疗法预防和治疗利什曼病的免疫检查点靶点
Front Immunol. 2017 Nov 8;8:1492. doi: 10.3389/fimmu.2017.01492. eCollection 2017.